News
TLPPF
11.97
NaN%
--
Telix Wins FDA Fast Track for Pre-Biopsy Prostate Cancer Imaging Program
TipRanks · 12h ago
Ord Minnett Remains a Buy on Telix Pharmaceuticals (TLPPF)
TipRanks · 1d ago
Weekly Report: what happened at TLPPF last week (0921-0925)?
Weekly Report · 2d ago
Telix Director David Gill Boosts Nasdaq ADS Stake
TipRanks · 5d ago
Telix Pharmaceuticals Issues New Shares Under Employee Stock Plan
TipRanks · 5d ago
Citi Remains a Buy on Telix Pharmaceuticals (TLPPF)
TipRanks · 09/23 00:09
Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)
TipRanks · 09/22 23:35
Jarden Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
TipRanks · 09/22 23:35
Telix upgraded to Outperform from Sector Perform at RBC Capital
TipRanks · 09/22 09:05
RBC upgrades Telix to Outperform on ITM deal benefits
TipRanks · 09/22 09:05
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TipRanks · 09/22 01:35
Telix Secures ASX Waivers to Support US$1.65bn ITM Acquisition
TipRanks · 09/21 22:57
Weekly Report: what happened at TLPPF last week (0914-0918)?
Weekly Report · 09/21 09:30
Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint
Seeking Alpha · 09/21 04:52
Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
TipRanks · 09/21 02:05
Telix to Acquire ITM in US$1.65 Billion Deal to Build Radiopharmaceutical Powerhouse
TipRanks · 09/20 23:30
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Barchart · 09/20 19:55
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
Telix Pharmaceuticals (TLPPF) Gets a Buy from Canaccord Genuity
TipRanks · 09/18 00:05
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement
Seeking Alpha · 09/16 20:10
More
Webull provides a variety of real-time TLPPF stock news. You can receive the latest news about Telix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TLPPF
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.